

Ad hoc announcement pursuant to Art. 53 LR

CPH Group adjusts earnings forecast for 2025 – EBITDA remains in the range of CHF 50 million

The CPH Group expects EBITDA for the 2025 financial year to be in the region of CHF 50 million (previous year: CHF 53.8 million), with an EBIT below the previous year's level and a lower net result. This is primarily due to a slowdown in the global pharmaceutical packaging market, unfavorable currency conditions, higher depreciation and financing costs, and the absence of one-time income from the previous year. Previously, a slightly increase in operating and net result compared to the previous year had been forecast. Sales are still expected to exceed last year's figures.

Perlen, 26 November 2025 – The decisive factor for the adjusted earnings forecast is a slowdown in the global pharmaceutical packaging market at Perlen Packaging. Global growth is currently below medium-term forecasts. In Europe, the market has declined so far this year. New production capacities in Europe and Latin America that are not yet fully utilized, as well as lower margins due to price pressure, had an impact on Perlen Packaging's profitability. At the same time, negative exchange rate developments weighed on earnings despite higher sales volumes than in the previous year. Perlen Packaging accelerated the implementation of comprehensive measures such as cost reductions, process and material optimizations, and the exploitation of additional synergy potential.

Mid-term targets confirmed

The momentum generated by the megatrends of health & demographics and energy, which are the most important value drivers for CPH Group, will remain intact in the medium and long term and offer the company attractive opportunities. The CPH Group remains committed to its communicated mid-term targets of annual revenue growth of 5-8 %, EBITDA margins of 16-18 %, and free cash flow margins of 8-10 % before acquisitions.

For further information on the current financial year and future business development, CPH Group refers to the publication of the 2025 annual report on 18 February 2026, and to the media and analyst conference taking place on the same day. For 2026, CPH Group anticipates stable business development and positive earnings growth in line with its mid-term targets.

Contacts

CPH Group AG

Dr. Alois Waldburg-Zeil, CEO, +41 41 455 80 00

Gerold Brüttsch, CFO, +41 41 455 80 00, investor.relations@cph.ch

Oliver Seifried, Head of Corporate Communications, +41 41 455 87 51, medien@cph.ch

About CPH Group AG

CPH Group AG is an internationally active and focused industrial group which is headquartered in Switzerland. CPH Group researches, develops, manufactures and distributes chemical products (www.zeochem.com) and pharmaceutical packaging films (www.perlen-packaging.com). The company and its subsidiaries maintain production facilities in Switzerland, Germany, Bosnia and Herzegovina, Hungary, Israel, the USA, Canada, Brazil, China, India and Singapore, and have a total worldwide workforce of some 1,200 personnel. The shares of CPH Group AG (ticker symbol: CPHN) are listed on the SIX Swiss Exchange. For further information visit www.cph.ch.

This media release contains future-oriented statements about CPH Group AG that are subject to risk and uncertainties. These statements reflect the management's opinions at the time of the release's compilation, but actual future events may deviate therefrom.